Neurocrine Biosciences (NBIX) Net Income towards Common Stockholders (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Net Income towards Common Stockholders for 17 consecutive years, with $144.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 34.33% year-over-year to $144.4 million; the trailing twelve-month figure through Jun 2026 stood at $705.5 million (up 102.56% YoY), and the FY2025 full-year result was $478.6 million, up 40.23% from the prior year.
• Net Income towards Common Stockholders fell to $144.4 million in Q2 2026 per NBIX's latest filing, from $197.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $209.5 million in Q3 2025 and bottomed at -$76.6 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged $87.0 million across 5 years, with a median of $92.2 million in 2022.
• The sharpest annual moves came in 2023 and 2026: Net Income towards Common Stockholders plunged 651.08% in 2023, then jumped 2405.06% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at $89.0 million in 2022, then soared by 65.96% to $147.7 million in 2023, then plunged by 30.2% to $103.1 million in 2024, then jumped by 49.08% to $153.7 million in 2025, then dropped by 6.05% to $144.4 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $144.4 million, $197.9 million, and $153.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.